Achieve significant weight reduction and enjoy a sustainable, healthier lifestyle with Yaras innovative, convenient approach
Using pharmacy receipt data anchored to initial GLP-1 prescriptions in 2021 from a large PBM, one early study revealed that only 32% GLP-1 patients remained on these weekly injections after 12 months and only 15% after two years.[16] This is an 85% two-year rejection rate not too far off from otherwise successful, consumer packaged goods brands Ive worked with
KPV's primary research literature focuses on mucosal inflammation and gut epithelial protection, with some documentation in skin wound models
These medicationsincluding popular brands like Ozempic, Wegovy, Mounjaro, and Zepboundhave gained widespread attention for their effectiveness in weight loss and blood sugar control
People with clinical obesity requiring significant medical intervention- GLP-1 medications produce 15 to 20% body weight reduction in clinical trials